Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women’s diagnostic and preventative care products from Common Sense Of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine’s Ontario, Canada. Easton has also entered the e-liquids and e-vaporizer market through the acquisition of revenue generating company, iBliss, Inc.
Medica Sur SAB de CV is a Mexico-based company primarily engaged in the healthcare sector. The Company manages hospitals, emergency and diagnostic centers, medical laboratories, organ and blood banks, as well as an accommodation place. It provides medical services within various specializations, such as anatomic pathology, cardiology, gynecology and obstetrics, neonatology, neurophysiology, odontology, oncology, ophthalmology, orthopedics, otolaryngology, pediatrics, radiology and imaging, as well as radiosurgery. In addition, the Company offers medical tourism services and distributes drugs. It forms a part of Mayo Clinic Care Network. The Company operates through a range of subsidiaries, such as Corporacion de Atencion Medica SA de CV, El Portal Medico SA de CV, Servicios de Administracion Hospitalaria SA de CV and Telemed SA de CV. The Company is owned by Neuco SA de CV.
Gedeon Richter plc (Hungarian: Richter Gedeon Nyrt.) is a Hungarian multinational pharmaceutical and biotechnology company headquartered in Budapest, Hungary. It is one of the largest companies of the industry in the Central and Eastern European region and has operations in over 40 countries.
The company sells products for gynecology, the central nervous system, and cardiology areas among other therapeutic areas. The company was established in Budapest by Gedeon Richter, a pharmacist, in 1901. The establishment of his firm marked the beginning of the development of the Hungarian pharmaceutical industry.
Gedeon Richter plc has a primary listing on the Budapest Stock Exchange and is a constituent of the BUX Index. It had a market capitalisation of approximately $4 billion as of November 2015, the third largest of any company with a primary listing on the Budapest Stock Exchange. It has secondary listings on Euronext.